ALK and lung carcinoma: A superior median PFS (9 months) was observed for patients with ALK-positive lung cancer treated with pemetrexed compared to patients with EGFR mutant (PFS 5.5 months), KRAS mutant (PFS 7 months), or “triple negative” (ALK fusion negative, wild-type EGFR, and wild-type KRAS; PFS 4 months) lung cancer [84].